PL2714707T3 - Krystalizacja chlorowodorku epirubicyny - Google Patents

Krystalizacja chlorowodorku epirubicyny

Info

Publication number
PL2714707T3
PL2714707T3 PL12735774T PL12735774T PL2714707T3 PL 2714707 T3 PL2714707 T3 PL 2714707T3 PL 12735774 T PL12735774 T PL 12735774T PL 12735774 T PL12735774 T PL 12735774T PL 2714707 T3 PL2714707 T3 PL 2714707T3
Authority
PL
Poland
Prior art keywords
crystallization
epirubicin hydrochloride
epirubicin
hydrochloride
Prior art date
Application number
PL12735774T
Other languages
English (en)
Inventor
Tero Kunnari
Original Assignee
Medac Gesellschaft für klinische Spezialpräparate mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medac Gesellschaft für klinische Spezialpräparate mbH filed Critical Medac Gesellschaft für klinische Spezialpräparate mbH
Publication of PL2714707T3 publication Critical patent/PL2714707T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/24Condensed ring systems having three or more rings
    • C07H15/252Naphthacene radicals, e.g. daunomycins, adriamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/44Preparation of O-glycosides, e.g. glucosides
    • C12P19/56Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound to a condensed ring system having three or more carbocyclic rings, e.g. daunomycin, adriamycin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL12735774T 2011-05-31 2012-05-25 Krystalizacja chlorowodorku epirubicyny PL2714707T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011103751A DE102011103751A1 (de) 2011-05-31 2011-05-31 Kristallisierung von Epirubicinhydrochlorid
US201161493034P 2011-06-03 2011-06-03
EP12735774.7A EP2714707B1 (de) 2011-05-31 2012-05-25 Kristallisierung von epirubicinhydrochlorid

Publications (1)

Publication Number Publication Date
PL2714707T3 true PL2714707T3 (pl) 2017-06-30

Family

ID=47173398

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12735774T PL2714707T3 (pl) 2011-05-31 2012-05-25 Krystalizacja chlorowodorku epirubicyny

Country Status (14)

Country Link
US (1) US9657047B2 (pl)
EP (1) EP2714707B1 (pl)
JP (2) JP6014844B2 (pl)
KR (1) KR20140006092A (pl)
CN (1) CN103827129A (pl)
AR (1) AR086519A1 (pl)
AU (1) AU2012265238B2 (pl)
DE (1) DE102011103751A1 (pl)
HR (1) HRP20170329T1 (pl)
HU (1) HUE031795T2 (pl)
PL (1) PL2714707T3 (pl)
RU (1) RU2586117C2 (pl)
TW (1) TWI496789B (pl)
WO (1) WO2012163508A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2778171A1 (en) * 2013-03-15 2014-09-17 Synbias Pharma Ltd. Crystalline monohydrate of epirubicin hydrochloride
CN104861014B (zh) * 2015-06-03 2017-09-29 道中道(菏泽)制药有限公司 一种盐酸表阿霉素结晶的制备方法
CN109384822B (zh) * 2017-08-11 2021-08-03 鲁南制药集团股份有限公司 一种盐酸表柔比星晶型及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1506200A (en) 1975-04-30 1978-04-05 Farmaceutici Italia Glycosides
US4345068A (en) 1979-11-22 1982-08-17 Farmitalia Carlo Erba S.P.A. Process for the preparation of 4'-epidaunorubicin, 3',4'-diepidaunorubicin, their doxorubicin analogs, and intermediates used in said process
IT1155446B (it) 1982-12-23 1987-01-28 Erba Farmitalia Procedimento per la purificazione di glucosidi antraciclinonici mediante adsobimento selettivo su resine
GB8426672D0 (en) 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
ATE195526T1 (de) * 1996-12-16 2000-09-15 Pharmachemie Bv Verfahren zur herstellung von epirubicin oder zusatzsalzen davon, von daunorubicin
AU1259899A (en) 1997-11-28 1999-06-16 Sumitomo Pharmaceuticals Company, Limited Crystalline amrubicin hydrochloride
ES2356284T3 (es) * 1997-12-05 2011-04-06 Mercian Corporation Antibiótico de antraciclina cristalino y procedimiento para su producción.
US20020048610A1 (en) * 2000-01-07 2002-04-25 Cima Michael J. High-throughput formation, identification, and analysis of diverse solid-forms
ATE520702T1 (de) * 2003-07-02 2011-09-15 Solux Corp Thermisch stabiles kristallines epirubicin- hydrochlorid und herstellungsverfahren dafür
US20090099346A1 (en) 2003-07-02 2009-04-16 Victor Matvienko Thermally stable crystalline epirubicin hydrochloride
US7388083B2 (en) * 2005-03-07 2008-06-17 Solux Corporation Epimerization of 4′-C bond and modification of 14-CH3-(CO)-fragment in anthracyclin antibiotics
CA2606390A1 (en) * 2005-05-11 2006-11-16 Sicor, Inc. Stable lyophilized anthracycline glycosides
US8802830B2 (en) * 2005-12-20 2014-08-12 Solux Corporation Synthesis of epirubicin from 13-dihydrodaunorubicine
JP2007261976A (ja) * 2006-03-28 2007-10-11 Meiji Seika Kaisha Ltd 抗腫瘍性アンスラサイクリン系抗生物質の製造法
ES2644422T3 (es) 2007-05-08 2017-11-28 Provivo Oy Cepas modificadas genéticamente que producen metabolitos de antraciclina útiles como fármacos para el cáncer
EP2315765B1 (en) 2008-06-18 2012-12-19 Lexicon Pharmaceuticals, Inc. Solid forms of (1r,2s,3r)-1-(2-(isoxazol-3-yl)-1h-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use
EP2636676A3 (en) * 2009-09-08 2014-01-01 Heraeus Precious Metals GmbH & Co. KG Crystallization of epidaunorubicin x HCl
KR101125460B1 (ko) * 2010-03-24 2012-03-28 동아제약주식회사 에피루비신 염산염의 신규한 결정형
CN102120750B (zh) * 2011-01-30 2013-04-03 山东新时代药业有限公司 一种盐酸表柔比星的纯化方法

Also Published As

Publication number Publication date
JP2016175938A (ja) 2016-10-06
CN103827129A (zh) 2014-05-28
JP6014844B2 (ja) 2016-10-26
AU2012265238B2 (en) 2016-05-12
HRP20170329T1 (hr) 2017-04-21
DE102011103751A1 (de) 2012-12-06
US20120309948A1 (en) 2012-12-06
KR20140006092A (ko) 2014-01-15
EP2714707A1 (de) 2014-04-09
AR086519A1 (es) 2013-12-18
TWI496789B (zh) 2015-08-21
RU2586117C2 (ru) 2016-06-10
HUE031795T2 (en) 2017-08-28
AU2012265238A1 (en) 2014-01-09
RU2013158684A (ru) 2015-07-10
WO2012163508A1 (de) 2012-12-06
TW201302773A (zh) 2013-01-16
JP2014515381A (ja) 2014-06-30
EP2714707B1 (de) 2016-12-14
US9657047B2 (en) 2017-05-23

Similar Documents

Publication Publication Date Title
HK1244183A1 (zh) Ivacaftor的氘化衍生物
HK1199728A1 (en) Polymorphic form of pridopidine hydrochloride
EP2596675A4 (en) METHODS OF MANAGING MULTIPLE TIME ADVANCE GROUPS
HUE047354T2 (hu) Ivacaftor deuterizált származékai
EP2742051A4 (en) AMORPHIC FORM OF DOLUTEGRAVIR
IL230976A0 (en) Crystalline forms of cvezitaxel
HK1192562A1 (zh) 取代的苯甲酰胺衍生物
PL2505243T3 (pl) Urządzenie do krystalizacji
IL233001A0 (en) New iso-ergoline histories
GB2512737B (en) Micro-Fermentation of cocoa
PL2737805T3 (pl) Nasączony czekoladą wyrób cukierniczy
EP2684869A4 (en) PREPARATION OF 3-MERCAPOTOPROPIONATES
EP2680843A4 (en) DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS
PL2714707T3 (pl) Krystalizacja chlorowodorku epirubicyny
SG2014008858A (en) Crystallization methods
IL230977A (en) A crystalline form of relapaldib
EP2782902A4 (en) DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
PL395425A1 (pl) Sposób wytwarzania chlorowodorku 2-amino-N-tert-butylo-2- cyjanoacetamidu
GB201102475D0 (en) Method of reducing offset
IL231452A0 (en) Amorphous form of dolutegravir
PL120112U1 (pl) Pustak scienny
PL119877U1 (pl) Pustak scienny
GB201100642D0 (en) Clock adjustment